U
Ulpiano Jimenez
Publications - 12
Citations - 5347
Ulpiano Jimenez is an academic researcher. The author has contributed to research in topics: Lung cancer & Erlotinib. The author has an hindex of 8, co-authored 12 publications receiving 4803 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
Vicente Alberola,Carlos Camps,Mariano Provencio,Dolores Isla,Rafael Rosell,C. Vadell,Isabel Bover,Ana Ruiz-Casado,P. Azagra,Ulpiano Jimenez,Jose-Luis Gonzalez-Larriba,Pilar Diz,Felipe Cardenal,Angel Artal,Alfredo Carrato,Serafin Morales,José Jurado Sánchez,R. de las Peñas,Enriqueta Felip,Guillermo Lopez-Vivanco +19 more
TL;DR: CG remains a standard regimen for first-line treatment of advanced NSCLC on the basis of results, and no differences in median survival or time to progression were observed.
Journal ArticleDOI
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.
Rafael Rosell,Laia Perez-Roca,Jose Javier Sanchez,Manuel Cobo,Teresa Moran,Imane Chaib,Mariano Provencio,Manuel Domine,María Ángeles Sala,Ulpiano Jimenez,Pilar Diz,Isidoro Barneto,Jose Antonio Macias,Ramon De Las Penas,Silvia Catot,Dolores Isla,Jose Miguel Sanchez,Rafael Ibeas,Guillermo Lopez-Vivanco,Juana Oramas,Pedro Mendez,Noemi Reguart,R. Blanco,Miquel Taron +23 more
TL;DR: Chemotherapy customized according to BRCA1 expression levels is associated with excellent median and 2-year survival for some subsets of NSCLC patients, and RAP80 could play a crucial modulating effect on this model of customized chemotherapy.
Journal ArticleDOI
Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer
Sara Simonetti,Miguel Angel Molina,Cristina Queralt,Itziar de Aguirre,Clara Mayo,Jordi Bertran-Alamillo,Jose Javier Sanchez,José Luis González-Larriba,Ulpiano Jimenez,Dolores Isla,Teresa Moran,Santiago Viteri,Carlos Camps,Rosario García-Campelo,Bartomeu Massuti,Susana Benlloch,Santiago Ramón y Cajal,Miquel Taron,Rafael Rosell +18 more
TL;DR: IHC with mutation-specific mAbs against EGFR is a promising method for detecting EGFR mutations in NSCLC patients, however these mAbs should be validated with additional studies to clarify their possible role in routine clinical practice.
Journal ArticleDOI
Spanish customized adjuvant trial (SCAT) based on BRCA1 mRNA levels
M. Cobo,B. Massuti,Teresa Moran,Imane Chaib,L. Perez-Roca,Ulpiano Jimenez,D. Aguiar Bujanda,Jose-Luis Gonzalez-Larriba,J. Gómez,Rafael Rosell +9 more
TL;DR: Adjuvant chemotherapy was customized based on BRCA1 mRNA levels in 84/100 completely resected N1 and N2 NSCLC p, and median survival has not been reached in p with high or intermediate BRCa1 levels.